{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:48:58Z","timestamp":1777420138779,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted on PubMed from origin to April 2023, using the search terms \u201cMYK-461,\u201d \u201cmavacamten,\u201d \u201cCK-3773274,\u201d and \u201caficamten.\u201d Studies were limited to English-based literature, human subjects, and clinical trials resulting in the inclusion of 13 articles. ClinicalTrials.gov was also used with the same search terms for ongoing and completed trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Only phase II and III studies were included in this review except for pharmacokinetic studies that were used to describe drug properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>CMIs enable cardiac muscle relaxation by decreasing the number of myosin heads that can bind to actin and form cross-bridges. Mavacamten, the first Food and Drug Administration (FDA)-approved drug in this class, has been shown to improve hemodynamic, functional, and quality of life measures in HCM with obstruction. In addition, aficamten is likely to become the next FDA-approved CMI with promising phase II data and an ongoing phase III trial expected to release results in the next year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:<\/jats:title>\n                    <jats:p>CMIs provide a novel option for obstructive hypertrophic cardiomyopathy, particularly in those not suitable for septal reduction therapy. Utilization of these agents requires knowledge of drug interactions, dose titration schemes, and monitoring parameters for safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CMIs represent a new class of disease-specific drugs for treatment of HCM. Cost-effectiveness studies are needed to delineate the role of these agents in patient therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231180000","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T01:00:20Z","timestamp":1686963620000},"page":"273-285","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8071-0226","authenticated-orcid":false,"given":"Alyssa","family":"Sykuta","sequence":"first","affiliation":[{"name":"Department of Pharmacy, OhioHealth Riverside Methodist Hospital, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6176-9305","authenticated-orcid":false,"given":"Connie H.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OhioHealth Riverside Methodist Hospital, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OhioHealth Riverside Methodist Hospital, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie I.","family":"Rine","sequence":"additional","affiliation":[{"name":"Central Ohio Poison Center, Nationwide Childrens Hospital, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OhioHealth Riverside Methodist Hospital, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-3397","authenticated-orcid":false,"given":"Adam","family":"Smith","sequence":"additional","affiliation":[{"name":"Advanced Heart and Vascular Center, OhioHealth Riverside Methodist Hospital, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"bibr1-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.92.4.785"},{"key":"bibr2-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.019"},{"key":"bibr3-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.08.045"},{"key":"bibr4-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1710575"},{"key":"bibr5-10600280231180000","unstructured":"Suboc T. Hypertrophic cardiomyopathy. Merck Manuals Professional Version. Published 2022. Accessed May 15, 2022. https:\/\/www.merckmanuals.com\/professional\/cardiovascular-disorders\/cardiomyopathies\/hypertrophic-cardiomyopathy"},{"key":"bibr6-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"bibr7-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2018.08.062"},{"key":"bibr8-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.24328"},{"key":"bibr9-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1495856"},{"key":"bibr10-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01290"},{"key":"bibr11-10600280231180000","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3016"},{"key":"bibr12-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.064"},{"key":"bibr13-10600280231180000","unstructured":"A long-term safety extension study of mavacamten in adults who have completed MAVERICK-HCM or EXPLORER-HCM (MAVA-LTE). ClinicalTrials.gov identifier: NCT03723655. Published May 12, 2022. Accessed April 27, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03723655"},{"key":"bibr14-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.04.008"},{"key":"bibr15-10600280231180000","unstructured":"A study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive HCM (EXPLORER-CN). ClinicalTrials.gov identifier: NCT05174416. Published January 19, 2022. Accessed November 15, 2022. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT05174416"},{"key":"bibr16-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.062534"},{"key":"bibr17-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"bibr18-10600280231180000","unstructured":"A study of mavacamten in obstructive hypertrophic cardiomyopathy (HORIZON-HCM). ClinicalTrials.gov identifier: NCT05414175. Published February 28, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05414175"},{"key":"bibr19-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014986"},{"key":"bibr20-10600280231180000","unstructured":"Extension study of mavacmten (MYK-461) in adults with symptomatic obstructive hypertrophic cardiomyopathy previously enrolled in PIONEER (PIONEER-OLE). ClinicalTrials.gov identifier: NCT03496168. Published January 28, 2022. Accessed May 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03496168"},{"key":"bibr21-10600280231180000","unstructured":"A prospective registry study to assess real-world patient characteristics, treatment patterns, and longitudinal outcomes in patients receiving mavacamten and other treatments for symptomatic obstructive hypertrophic cardiomyopathy (Obstructive HCM) (DISCOVER-HCM). ClinicalTrials.gov identifier: NCT05489705. Published February 28, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05489705"},{"key":"bibr22-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"bibr23-10600280231180000","unstructured":"Mavacamten (CAMZYOS) [package insert]. Bristol-Myers Squibb Company; 2022."},{"key":"bibr24-10600280231180000","unstructured":"A study of mavacamten in participants with HFpEF and elevation of NT-proBNP with or without elevation of cTnT (EMBARK-HFpEF). ClinicalTrials.gov identifier: NCT04766892. Published February 9, 2022. Accessed May 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04766892"},{"key":"bibr25-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"bibr26-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"bibr27-10600280231180000","unstructured":"A study of mavacamten in non-obstructive hypertrophic cardiomyopathy (ODYSSEY-HCM). ClinicalTrials.gov identifier: NCT05582395. Published March 30, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05582395"},{"key":"bibr28-10600280231180000","unstructured":"Francis S. Bristol Myers Squibb announces data from EXPLORER-LTE demonstrating sustained improvements in clinically meaningful cardiovascular outcomes at weeks 48 and 84 in patients with symptomatic obstructive hypertrophic cardiomyopathy receiving macavamten. Published April 4, 2022. Accessed May 13, 2022. https:\/\/news.bms.com\/news\/corporate-financial\/2022\/Bristol-Myers-Squibb-Announces-Data-from-EXPLORER-LTE-Demonstrating-Sustained-Improvements-in-Clinically-Meaningful-Cardiovascular-Outcomes-at-Weeks-48-and-84-in-Patients-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-Receiving-Mavacamten\/default.aspx"},{"key":"bibr29-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.020"},{"key":"bibr30-10600280231180000","unstructured":"CY 6022 is an open label study to collect long-term safety and tolerability data for aficamten (CK-3773274) (FOREST-HCM). ClinicalTrials.gov identifier: NCT04848506. Published February 2, 2023. Accessed March 31, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04848506?cond=aficamten&draw=2&rank=1"},{"key":"bibr31-10600280231180000","unstructured":"CY 6031 study will evaluate the effects of treatment with aficamten (CK-3773274) over a 24-week period on cardiopulmonary exercise capacity and health status in patients with symptomatic oHCM (SEQUOIA-HCM). ClinicalTrials.gov identifier: NCT05186818. Published February 21, 2023. Accessed March 31, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05186818?cond=aficamten&draw=2&rank=2"},{"key":"bibr32-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.0252"},{"key":"bibr33-10600280231180000","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.11.006"},{"key":"bibr34-10600280231180000","unstructured":"Mavacamten. Lexi-drugs. Lexicomp; 2020."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231180000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231180000","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231180000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:13Z","timestamp":1777374793000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231180000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1177\/10600280231180000"],"URL":"https:\/\/doi.org\/10.1177\/10600280231180000","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}